Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2

详细信息    查看全文

• 作者：Masanobu Tsubaki ; Takao Satou ; Tatsuki Itoh ; Motohiro Imano ; Masashi Yanae ; Chisato Kato ; Risa Takagoshi ; Makiko Komai ; Shozo Nishida
• 关键词：OPG ; osteoprotegerin ; M-CSF ; macrophage-colony stimulating factor ; MEK ; mitogen activated protein kinase kinase ; ERK ; extracellular signal regulated kinase ; MAPK ; mitogen activated protein kinase ; FPP ; farnesyl pyrophosphate ; GGPP ; geranylgeranyl pyrophos
• 刊名：Molecular and Cellular Endocrinology
• 出版年：2012
• 出版时间：25 September, 2012
• 年：2012
• 卷：361
• 期：1-2
• 页码：219-231
• 全文大小：2037 K

文摘

Osteoclast differentiation is influenced by receptor activator of the NF-¦ÊB ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and CD9, which are expressed on bone marrow stromal cells and osteoblasts. In addition, osteoprotegerin (OPG) is known as an osteoclastogenesis inhibitory factor. In this study, we investigated whether bisphosphonates and statins increase OPG expression and inhibit the expression of CD9, M-CSF, and RANKL in the bone marrow-derived stromal cell line ST2. We found that bisphosphonates and statins enhanced OPG mRNA expression and inhibited the expression of CD9, M-CSF, and RANKL mRNA. Futhermore, bisphosphonates and statins decreased the membrane localization of Ras and phosphorylated ERK1/2, and activated the p38MAPK. This indicates that bisphosphonates and statins enhanced OPG expression, and inhibited the expression of CD9, M-CSF, and RANKL through blocking the Ras/ERK pathway and activating p38MAPK. Accordingly, we believe that its clinical applications will be investigated in the future for the development of osteoporosis therapy.